Brief: Surgical Innovations Says Trading In The First Half Of The Year Was Broadly Flat

Surgical Innovations

30/09/2026 08:35

Sept 30 (Reuters) - Surgical Innovations Group PLC SUNU.L:
SURGICAL INNOVATIONS:US SALES NOW NORMALISED FOLLOWING WAREHOUSE TRANSITION, BUT SHORTFALL INCURRED DURING H1 NOT EXPECTED TO BE RECOVERED DURING 2026 (ADDS DROPPED WORD 'US')
SURGICAL INNOVATIONS: TARIFF-RELATED IMPACT ON MARKET OPPORTUNITIES EXPECTED TO REMAIN HEADWIND IN H2, MAY CONTINUE TO CONSTRAIN US GROWTH IN NEAR TERM (ADDS DROPPED WORD 'US')
SURGICAL INNOVATIONS H1 ADJUSTED EBITDA GBP 33 THOUSAND
SURGICAL INNOVATIONS H1 GROSS PROFIT GBP 1.748 MILLION
SURGICAL INNOVATIONS H1 REVENUE GBP 6.019 MILLION
SURGICAL INNOVATIONS H1 EBIT GBP -230 THOUSAND
SURGICAL INNOVATIONS GROUP: TRADING HEADWINDS EXPERIENCED IN H1 ARE EXPECTED TO PERSIST IN CERTAIN MARKETS, MOST NOTABLY THE UNITED STATES
SURGICAL INNOVATIONS GROUP: HAS ADEQUATE CASH RESOURCES AND INVOICE FINANCING FACILITY TO CONTINUE TO OPERATE FOR THE FORESEEABLE FUTURE
SURGICAL INNOVATIONS: EXPECT SOME EXTERNAL HEADWINDS, PARTICULARLY US TARIFFS, TO PERSIST DURING H2, THOUGH REMAIN CONFIDENT IN OUTLOOK FOR BUSINESS
SURGICAL INNOVATIONS: TRADING IN THE FIRST HALF OF THE YEAR WAS BROADLY FLAT
SURGICAL INNOVATIONS: ACTIVELY EXPLORING ADDITIONAL ROUTES TO MARKET AND ALTERNATIVE DISTRIBUTION OPPORTUNITIES IN THE US
SURGICAL INNOVATIONS: THESE INITIATIVES ARE NOT EXPECTED TO MAKE A MATERIAL CONTRIBUTION TO 2026 REVENUES
SURGICAL INNOVATIONS: FURTHER COST-DOWN INITIATIVES ARE PLANNED DURING H2
SURGICAL INNOVATIONS: SEEING ENCOURAGING SIGNS FROM ITS INVESTMENT IN SALES TEAM AND INTRODUCTION OF NEW THIRD-PARTY PRODUCTS
SURGICAL INNOVATIONS: REMAINS CONFIDENT IN THE UNDERLYING POTENTIAL OF THE BUSINESS AND ITS PROSPECTS FOR THE REMAINDER OF 2026
Further company coverage: SUNU.L

 ((Reuters.Briefs@thomsonreuters.com;))